Synthonics Names New CEO

Blacksburg, VA – October16, 2017 – Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that it has appointed John Tinkham as Chief Executive Officer and Chairman of the Board. He succeeds Ken Slepicka in these roles.

John Tinkham, a founder and director of the company, stated that “I am thankful for this opportunity and very excited by the challenges it presents. I look forward to working closely with our team and our partners to accelerate the development and commercialization of our lead compounds

Ken Slepicka, will remain with the company as a director and will focus his efforts on overseeing and monetizing the company’s novel cannabinoid purification process and its product development.

Dr. Tom Piccariello, President and Chief Science Officer of Synthonics stated that ”We are very pleased that John Tinkham has accepted the CEO position. We look forward to continued success of the company. We are also grateful to Ken Slepicka for his service to the company as CEO and we look forward to Ken’s new role to advance our cannabinoid projects."